With lack of buyers Enzon returns LNA programs to Santaris
This article was originally published in Scrip
Executive Summary
All rights, data, products and intellectual property related to Enzon Pharmaceutical's license for Santaris Pharma's locked nucleic acid (LNA) platform will revert to Santaris along with an undisclosed amount of money as Enzon works on returning cash to shareholders.